How Abcuro is targeting specific T cells to treat a rare muscle-wasting disease

With $155 million in new funding from a crossover syndicate, Abcuro is conducting a pivotal study testing its thesis that depleting specific sets of cytotoxic T cells can treat a rare muscle-wasting disease and other immunological indications.

Launched in 2015 with rights to a first-in-class program from Massachusetts General Hospital targeting KLRG1, Abcuro Inc. has begun a Phase II/III study testing the subcutaneous therapy for inclusion body myositis (IBM)...